Phosphodiesterase inhibitors suppress α2-adrenoceptor-mediated 5-hydroxytryptamine release from tracheae of newborn rabbits

Freitag, Anke; Wessler, Ignaz; Racké, Kurt

doi:10.1016/s0014-2999(98)00439-7

Cited by 22 publications

(13 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The PDE inhibitors decrease enzyme activity, and the level of cyclic nucleotides remains high. Among possible inhibitors of intracellular PDE, IBMX and dipyridamole were tested in the present study because, in animal cells, they similarly inhibit the cyclic nucleotides' PDEs, which are implicated in cGMP deactivation (Freitag, 1998). In our experiments, only dipyridamole was able to elevate cGMP concentration ( Figure 2).…”

Section: Article In Pressmentioning

confidence: 75%

Involvement of cyclic GMP in phytochrome-controlled flowering of Pharbitis nil

Szmidt-Jaworska

Jaworski

Kopcewicz

2008

Journal of Plant Physiology

View full text Add to dashboard Cite

Section: Article In Pressmentioning

confidence: 75%

Involvement of cyclic GMP in phytochrome-controlled flowering of Pharbitis nil

Szmidt-Jaworska

Jaworski

Kopcewicz

2008

Journal of Plant Physiology

View full text Add to dashboard Cite

“…There is some evidence to suggest that PDE inhibitors may alter serotonin levels (Freitag et al, 1998). However, the exact interactions between PDE inhibitors and SSRIs that give rise to these effects are unknown.…”

Section: Discussionmentioning

confidence: 99%

Zaprinast, a Phosphodiesterase 5 Inhibitor, Overcomes Sexual Dysfunction Produced by Fluoxetine, a Selective Serotonin Reuptake Inhibitor in Hamsters

Frye

Rhodes

2003

Neuropsychopharmacol

View full text Add to dashboard Cite

A high incidence of sexual dysfunction among women is reported in the clinical literature. Little experimental investigation has been initiated on the ability of phosphodiesterase (PDE) inhibitors to overcome deficits in sexual functioning because of selective serotonin reuptake inhibitors (SSRIs). The effects of fluoxetine, an SSRI, and zaprinast, a PDE-5 inhibitor, on the lateral displacement response (used as a measure of sensitivity to reproductively relevant stimuli) of hamsters in behavioral estrus were investigated. In Experiment 1, hamsters that were maximally sensitive to reproductively relevant stimuli because they were at the peak of behavioral estrus were administered fluoxetine (10 mg/kg, i.p.); they had significantly decreased lateral displacement responses compared to vehicleadministered hamsters. In Experiment 2, hamsters that were relatively less sensitive to sexual stimuli because they were at the termination of behavioral estrus were administered zaprinast (3 mg/kg; i.p.); they had significantly enhanced lateral displacement responses compared to responses seen following vehicle administration. In Experiment 3, fluoxetine-induced deficits in the lateral displacement of hamsters at the peak of behavioral estrus were overcome by the coadministration of zaprinast. These data confirm previous findings that sexual dysfunction can be induced by SSRIs and extend the current knowledge to suggest that administration of a PDE-5 inhibitor can override SSRI-induced deficits in sexual functioning.

show abstract

“…Topical application of zaprinast (1.5 μ m ), a specific inhibitor of phosphodiesterases 5 and 6 also blocked the acceleration, while application of T0156 (2.3 n m ), a specific inhibitor of phosphodiesterase 5, had no effect. The concentration of each inhibitor topically applied was approximately 10 times the corresponding IC 50 value (10–13). These results suggest that phosphodiesterase 6 is involved in the effect of red light in accelerating the recovery of the epidermal permeability barrier.…”

Section: Resultsmentioning

confidence: 99%

“…3‐Isobutyl‐1‐methylxanthine (IBMX, a non‐selective PDE inhibitor, IC 50 for PDE: 13–50 μ m (10)) and T0156 hydrochloride (a selective PDE5 inhibitor, IC 50 for PDE5: 0.23 n m ) (11) were purchased from Tocris (Ellisville, MO, USA). Zaprinast (PDE5, 6, 9 inhibitor, IC 50 for PDE5: 0.76 μ m (12), PDE6: 0.15 μ m (13)), was purchased from Sigma (St Louis, MO, USA).…”

Section: Methodsmentioning

confidence: 99%

Phosphodiesterase inhibitors block the acceleration of skin permeability barrier repair by red light

Goto

Ikeyama

Tsutsumi

et al. 2011

Experimental Dermatology

View full text Add to dashboard Cite

We previously demonstrated that exposure to red light (550-670 nm) accelerates epidermal permeability barrier recovery after barrier disruption. Furthermore, we showed that photosensitive proteins, originally found in retina, are also expressed in epidermis. In retina, transducin and phosphodiesterase 6 play key roles in signal transmission. In this study, we evaluate the role of phosphodiesterese 6 in the acceleration by red light of epidermal permeability barrier recovery. Immunohistochemical study and reverse transcription-PCR assays confirmed the expression of both transducin and phosphodiesterase 6 in epidermal keratinocytes. Topical application of 3-isobutyl-1-methylxanthine, a non-specific phosphodiesterase inhibitor, blocked the acceleration of the barrier recovery by red light. Topical application of zaprinast, a specific inhibitor of phosphodiesterases 5 and 6, also blocked the acceleration, whereas T0156, a specific inhibitor of phosphodiesterase 5, had no effect. Red light exposure reduced the epidermal hyperplasia induced by barrier disruption under low humidity, and the effect was blocked by pretreatment with zaprinast. Our results indicate phosphodiesterase 6 is involved in the recovery-accelerating effect of red light on the disrupted epidermal permeability barrier.

show abstract

Phosphodiesterase inhibitors suppress α2-adrenoceptor-mediated 5-hydroxytryptamine release from tracheae of newborn rabbits

Cited by 22 publications

References 18 publications

Involvement of cyclic GMP in phytochrome-controlled flowering of Pharbitis nil

Involvement of cyclic GMP in phytochrome-controlled flowering of Pharbitis nil

Zaprinast, a Phosphodiesterase 5 Inhibitor, Overcomes Sexual Dysfunction Produced by Fluoxetine, a Selective Serotonin Reuptake Inhibitor in Hamsters

Phosphodiesterase inhibitors block the acceleration of skin permeability barrier repair by red light

Contact Info

Product

Resources

About